Utilizing an unbiased, high-throughput screen, we have identified a multitargeted kinase (JAK/CSF1R) inhibitor (pacritinib) that depletes LAM and prolongs survival in PTCL-bearing mice, and is now being explored in an investigator-initiated clinical trial in PTCL (ClinicalTrials.gov Identifier: NCT04858256). Here, CSF1R is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.